Business
Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
Five abstracts accepted for presentation, including data demonstrating bilirubin normalization with LIVMARLI in PFIC Sleep improvement data from MARCH-PFIC
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nFive abstracts accepted for presentation, including data demonstrating bilirubin normalization with LIVMARLI in PFIC\n\n\n\nSleep improvement data from MARCH-PFIC study included among ‘Best of EASL’ presentations\n\n\n\nMaintenance of response in patients with PFIC selected as late-breaker presentation\n\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present data at the upcoming International Liver Congress of the European Association for the Study of the Liver taking place June 21-24, 2023 in Vienna, Austria.\n\n\nData from Mirum’s studies of LIVMARLI® (maralixibat) oral solution include oral and poster presentations:\n\n\nAbstract OS-072: Maralixibat leads to significant reductions in bilirubin for patients with Progressive Familial Intrahepatic Cholestasis: Data from MARCH-PFIC\nOral presentation during Abstract Session 2: Immune-mediated and cholestatic diseases\nFriday, June 23, 2023 from 5:45-6:00pm CET\nAuthor: Dr. Lorenzo D’Antiga, Papa Giovanni XXIII Hospital, Bergamo, Italy\n\n\nLBP-35: Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): Data from the MARCH-ON study\n*Late-breaker poster presentation*\nJune 21, 2023, throughout the day\nAuthor: Professor Richard J. Thompson, King’s College, London, United Kingdom\n\n\nWED-257: Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome\nPoster presentation during Poster Session: Immune-mediated and cholestatic diseases\nWednesday, June 21, 2023, throughout the day\nAuthor: Dr. Binita Kamath, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada\n\n\nWED-252: Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with Progressive Familial Intrahepatic Cholestasis: Data from MARCH-PFIC\n**Selected to be included as part of ‘Best of EASL’ presentation**\nPoster presentation during Poster Session: Immune-mediated and cholestatic disease\nWednesday, June 21, 2023, throughout the day\nAuthor: Professor Richard J. Thompson, King’s College, London, United Kingdom\n\n\nWED-282: Analysis of safety in maralixibat-treated participants with Progressive Familial Intrahepatic Cholestasis: Data from MARCH-PFIC\n*Poster to...